A five-step approach to personalise and simplify treatment, leading to higher efficacy

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more

The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Alcon acquired the historic ophthalmic instrument company in 2000

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups

A pioneer of refractive laser eye surgery in the UK, Professor David Gartry, MD, FRCS, FRCOphth, FCOptom, reached the milestone in the 36th year of his career

In the European Union and the United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

Social determinants of health challenge our existing expectations

Patients with GCA, an autoimmune disease, are at risk for sudden vision loss which can be permanent